AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21059094 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 333
Study 19009498 — intervention group
Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE) detected by cardiac magnetic resonance imaging in SSc patients
Number of subjects: 34
Study 19009498 — intervention group
Group type: COMPARATOR
Intervention: Control group (age, sex, and cardiovascular risk factors matched)
Number of subjects: 34
Study 16996844 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (1.5 mg/kg daily for 3 months)
Number of subjects: 102
Study 16996844 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (angiotensin-converting enzyme inhibitors, beta-blockers, diuretics)
Number of subjects: 102
Study 16996844 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 102
Study 16996844 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 102
Study 12000508 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 1% cream, once daily
Number of subjects: 106
Study 12000508 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole 2% cream, twice daily
Number of subjects: 106
Study 9509380 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (5.4 mg orally, 3 times daily, beginning at menses)
Number of subjects: 9
Study 9509380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9509380 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 9
Study 8585398 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 81
Study 8585398 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide/Amloride
Number of subjects: 81
Study 8585398 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 81
Study 2195890 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of netilmicin (2 g ceftriaxone also administered)
Number of subjects: 141
Study 2195890 — intervention group
Group type: COMPARATOR
Intervention: Conventional multiple-daily-dosing regimen of netilmicin (2 g ceftriaxone also administered)
Number of subjects: 141
Study 2195890 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of netilmicin
Number of subjects: 141
Study 2195890 — intervention group
Group type: COMPARATOR
Intervention: Conventional doses of netilmicin
Number of subjects: 141
Study 2195890 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily doses of netilmicin
Number of subjects: 141
Study 2195890 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing strategies
Number of subjects: 141
Study 2195890 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily dosing of netilmicin plus ceftriaxone
Number of subjects: 141
Study 627305 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g single dose)
Number of subjects: 60
Study 627305 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (2 g single dose)
Number of subjects: 60
Study 6804724 — intervention group
Group type: COMPARATOR
Intervention: EPSDT program (early and periodic screening, diagnosis and treatment)
Number of subjects: 1831
Study 29594838 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe OSAS group
Number of subjects: 60
Study 29594838 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate OSAS group
Number of subjects: 60
Study 29594838 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild OSAS group
Number of subjects: 60
Study 29594838 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 29594838 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior ciliary artery (PCA)
Number of subjects: 60
Study 29659924 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV)
Number of subjects: 600
Study 29659924 — intervention group
Group type: COMPARATOR
Intervention: Control (no PRV)
Number of subjects: 600
Study 29659924 — intervention group
Group type: EXPERIMENTAL
Intervention: PRV
Number of subjects: 600
Study 27835720 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-adjusting Positive Airway Pressure (PAP) technology, including auto-bilevel and adaptive servo-ventilation, with compliance > 20 h/wk (56 patients)
Number of subjects: 74
Study 27835720 — intervention group
Group type: COMPARATOR
Intervention: Partial PAP users with compliance < 20 h/wk (18 patients)
Number of subjects: 74
Study 24568890 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA‐PDT
Number of subjects: 14
Study 24568890 — intervention group
Group type: COMPARATOR
Intervention: Red light
Number of subjects: 14
Study 22534258 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk-based diet (HM40)
Number of subjects: 207
Study 22534258 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk-based diet (HM100)
Number of subjects: 207
Study 22534258 — intervention group
Group type: COMPARATOR
Intervention: Control diet (human milk, formula, and bovine-based fortifier)
Number of subjects: 207
Study 21135795 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized local treatment combined with compression therapy
Number of subjects: 90
Study 21135795 — intervention group
Group type: COMPARATOR
Intervention: Control group (healers)
Number of subjects: 90
Study 21135795 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-healers
Number of subjects: 90
Study 21135795 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking aids usage
Number of subjects: 90
Study 17917828 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant 5‐fluorouracil (5FU) based chemotherapy
Number of subjects: 1025
Study 17917828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node ratio (LNR) in stage III colorectal cancer
Number of subjects: 1025
Study 17917828 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy in rectal cancer patients
Number of subjects: 1025
Study 15501929 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid retention in AMS group
Number of subjects: 51
Study 15501929 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Na+ levels
Number of subjects: 51
Study 15501929 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine Na+ and K+ excretion
Number of subjects: 51
Study 15501929 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine Na+-to-K+ ratio
Number of subjects: 51
Study 15501929 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidiuretic hormone levels
Number of subjects: 51
Study 11899188 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine-enriched solution (7.5 g/500 mL)
Number of subjects: 200
Study 11899188 — intervention group
Group type: COMPARATOR
Intervention: Standard blood cardioplegic solution (Control)
Number of subjects: 200
Study 10182416 — intervention group
Group type: EXPERIMENTAL
Intervention: ComputerLink (experimental group)
Number of subjects: 102
Study 10182416 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to ComputerLink)
Number of subjects: 102
Study 7621490 — intervention group
Group type: COMPARATOR
Intervention: Topical applications of amine fluoride solution (1%) - Group A (positive control)
Number of subjects: 354
Study 7621490 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical applications of amine fluoride solution (0.5% F) - Group B
Number of subjects: 354
Study 7621490 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical applications of amine fluoride solution (0.25% F) - Group C
Number of subjects: 354
Study 2689396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 20 mg/m2
Number of subjects: 24
Study 2689396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m2
Number of subjects: 24
Study 2689396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 40 mg/m2
Number of subjects: 24
Study 2689396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (all doses) with hyperthermia and radiation
Number of subjects: 24
Study 2689396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with hyperthermia and radiation
Number of subjects: 24
Study 282794 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-lead ECG and systolic time intervals (STI)
Number of subjects: 24
Study 30803885 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT mHealth intervention
Number of subjects: 234
Study 30803885 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 234
Study 26564271 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise program
Number of subjects: 70
Study 26564271 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise group (Control)
Number of subjects: 70
Study 26045114 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma intervention for preventing nausea and vomiting related to dimethyl sulfoxide in HCT patients
Number of subjects: 69
Study 26045114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aroma intervention)
Number of subjects: 69
Study 23458673 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-cocaine vaccine
Number of subjects: 114
Study 23458673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 21284801 — intervention group
Group type: EXPERIMENTAL
Intervention: TB-402 0.3 mg kg(‐1)
Number of subjects: 75
Study 21284801 — intervention group
Group type: EXPERIMENTAL
Intervention: TB-402 0.6 mg kg(‐1)
Number of subjects: 75
Study 21284801 — intervention group
Group type: EXPERIMENTAL
Intervention: TB-402 1.2 mg kg(‐1)
Number of subjects: 75
Study 21284801 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg
Number of subjects: 75
Study 21284801 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled TB-402 groups
Number of subjects: 75
Study 19222617 — intervention group
Group type: EXPERIMENTAL
Intervention: Lozenge
Number of subjects: 0
Study 19222617 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet
Number of subjects: 0
Study 19222617 — intervention group
Group type: COMPARATOR
Intervention: Spray
Number of subjects: 0
Study 19222617 — intervention group
Group type: COMPARATOR
Intervention: Gargle
Number of subjects: 0
Study 17341515 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered electronic questionnaire
Number of subjects: 370
Study 17341515 — intervention group
Group type: COMPARATOR
Intervention: Self-administered paper-and-pencil questionnaire
Number of subjects: 370
Study 17341515 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally-administered interview questionnaire
Number of subjects: 370
Study 15025836 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 20 mg
Number of subjects: 321
Study 15025836 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg
Number of subjects: 321
Study 15025836 — intervention group
Group type: EXPERIMENTAL
Intervention: eletriptan 80 mg
Number of subjects: 321
Study 15025836 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 321
Study 11980683 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety margin of 0 steps above DFT++
Number of subjects: 636
Study 11980683 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety margin of 1 step above DFT++
Number of subjects: 636
Study 11980683 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety margin of 2 steps above DFT++
Number of subjects: 636
Study 11980683 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety margin of 3 steps above DFT++
Number of subjects: 636
Study 11980683 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety margin of 4 steps above DFT++
Number of subjects: 636
Study 11980683 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 steps above DFT++
Number of subjects: 636
Study 11980683 — intervention group
Group type: COMPARATOR
Intervention: Maximal output
Number of subjects: 636
Study 11980683 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety margin of 4 to 6 J
Number of subjects: 636
Study 9794981 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen syrup (20 mg/mL, 0.25 mL per kg per dose, administered every 6 hours during fever)
Number of subjects: 230
Study 9794981 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching syrup, administered every 6 hours during fever)
Number of subjects: 230
Study 9794981 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen syrup
Number of subjects: 230
Study 9794981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 9098292 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil
Number of subjects: 211
Study 9098292 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas tamponade
Number of subjects: 211
Study 9098292 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphakic/pseudophakic eyes
Number of subjects: 211
Study 9098292 — intervention group
Group type: COMPARATOR
Intervention: Postoperative macular pucker
Number of subjects: 211
Study 9098292 — intervention group
Group type: EXPERIMENTAL
Intervention: Large retinal breaks (>= 2 disc diameters)
Number of subjects: 211
Study 9098292 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative visual acuity
Number of subjects: 211
Study 2180481 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals with larger amounts of carbohydrates
Number of subjects: 0
Study 2180481 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals with simple sugars
Number of subjects: 0
Study 2180481 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals with complex carbohydrates
Number of subjects: 0
Study 2180481 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich meals
Number of subjects: 0
Study 2180481 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich meals
Number of subjects: 0
Study 509345 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine administered immediately upon termination of anaesthesia
Number of subjects: 111
Study 509345 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine administered 30 minutes after the last dose of ketamine
Number of subjects: 111
Study 509345 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 111
Study 31775412 — intervention group
Group type: EXPERIMENTAL
Intervention: Obconic inextensible endoscopic tube
Number of subjects: 91
Study 31775412 — intervention group
Group type: COMPARATOR
Intervention: Extensible retractor system
Number of subjects: 91
Study 31775412 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study 30009735 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingfeihuayutongfu prescription (200 mL through nasal feeding, one dose per day for 7 days)
Number of subjects: 32
Study 30009735 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingfeihuayutongfu prescription
Number of subjects: 32
Study 30009735 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 32
Study 26803474 — intervention group
Group type: EXPERIMENTAL
Intervention: RETeval device using flicker electroretinography (ERG) and pupillography
Number of subjects: 468
Study 24902473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 509
Study 24902473 — intervention group
Group type: COMPARATOR
Intervention: Levetiracetam
Number of subjects: 509
Study 22626799 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhiatal esophagectomy after chemotherapy
Number of subjects: 30
Study 22626799 — intervention group
Group type: COMPARATOR
Intervention: Transhiatal esophagectomy without chemotherapy
Number of subjects: 30
Study 22626799 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhiatal esophagectomy with chemotherapy
Number of subjects: 30
Study 19845412 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 19845412 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 19845412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19845412 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological interventions (anger and behavioural management, person‐centred planning, nidotherapy)
Number of subjects: 0
Study 17697105 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl
Number of subjects: 8
Study 17697105 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaOCl
Number of subjects: 8
Study 17697105 — intervention group
Group type: EXPERIMENTAL
Intervention: 9% NaOCl
Number of subjects: 8
Study 15876639 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis time section A (from stimulus onset to 5 s after the stimulus)
Number of subjects: 8
Study 15876639 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis time section B (from 2 to 7 s after the stimulus)
Number of subjects: 8
Study 15876639 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis time section C (from 4 to 9 s after the stimulus)
Number of subjects: 8
Study 11738765 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthrax vaccine (AVA)
Number of subjects: 0
Study 11738765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9430010 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (EM) 250 mg intravenously
Number of subjects: 0
Study 9430010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9430010 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (EM)
Number of subjects: 0
Study 7892941 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal course of pregnancy
Number of subjects: 87
Study 2896401 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized hemodilution treatment (venesection and dextran 40 administration)
Number of subjects: 183
Study 2896401 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hemodilution treatment)
Number of subjects: 183
Study 30098962 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion furosemide
Number of subjects: 90
Study 30098962 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus furosemide
Number of subjects: 90
Study 30098962 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine
Number of subjects: 90
Study 30098962 — intervention group
Group type: COMPARATOR
Intervention: No low-dose dopamine
Number of subjects: 90
Study 26194361 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/taxane chemotherapy
Number of subjects: 808
Study 24150098 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral gluteus maximus advancing flap (BGMAF)
Number of subjects: 105
Study 24150098 — intervention group
Group type: COMPARATOR
Intervention: Limberg flap (LF)
Number of subjects: 105
Study 23855560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate sodium 135 mM
Number of subjects: 118
Study 23855560 — intervention group
Group type: COMPARATOR
Intervention: Dialysate sodium 140 mM
Number of subjects: 118
Study 20671038 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐alanine (5 g/day)
Number of subjects: 18
Study 20671038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 18971409 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-based intensive case management
Number of subjects: 137
Study 18971409 — intervention group
Group type: COMPARATOR
Intervention: Traditional intensive case management
Number of subjects: 137
Study 16003201 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified technique using a metallic grid and a modified Steinmann pin with a metallic handle (flag) for targeting.
Number of subjects: 2
Study 16003201 — intervention group
Group type: COMPARATOR
Intervention: Traditional freehand technique.
Number of subjects: 2
Study 12930237 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD) group
Number of subjects: 113
Study 12930237 — intervention group
Group type: COMPARATOR
Intervention: Non-VLCD group
Number of subjects: 113
Study 12930237 — intervention group
Group type: EXPERIMENTAL
Intervention: Completers (n = 55)
Number of subjects: 113
Study 12930237 — intervention group
Group type: COMPARATOR
Intervention: Noncompleters (n = 58)
Number of subjects: 113
Study 10931579 — intervention group
Group type: EXPERIMENTAL
Intervention: MnDPDP injection (5 micromol/kg)
Number of subjects: 546
Study 8860712 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption
Number of subjects: 19
Study 8860712 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-induced extracorporeal LDL precipitation (HELP)
Number of subjects: 19
Study 8860712 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran sulfate adsorption
Number of subjects: 19
Study 8860712 — intervention group
Group type: EXPERIMENTAL
Intervention: All procedures
Number of subjects: 19
Study 8247815 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/4-strength hydrogen peroxide (0.75%)
Number of subjects: 35
Study 8247815 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/2-strength hydrogen peroxide (1.5%)
Number of subjects: 35
Study 8247815 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 35
Study 2951794 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 100 micrograms and ipratropium bromide 40 micrograms per puff (2 puffs)
Number of subjects: 16
Study 2951794 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol 100 micrograms and ipratropium bromide 40 micrograms per puff (4 puffs)
Number of subjects: 16
Study 29580260 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretically informed, participant-centred, evidence-based behaviour change interventions to improve retention in trials.
Number of subjects: 0
Study 29580260 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of intervention acceptability and feasibility through focus groups.
Number of subjects: 0
Study 29580260 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of a ready-to-use evaluation framework for Studies Within A Trial.
Number of subjects: 0
Study 27056964 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter patent foramen ovale closure plus antiplatelet therapy
Number of subjects: 664
Study 27056964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy
Number of subjects: 664
Study 27056964 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet therapy alone
Number of subjects: 664
Study 27056964 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatal or nonfatal stroke
Number of subjects: 664
Study 27056964 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatal, life-threatening or major procedure- or device-related complications
Number of subjects: 664
Study 27056964 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatal, life-threatening or major haemorrhagic complications
Number of subjects: 664